Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck

Clinical trial NCT00077428 · COMPLETED

Trial details

NCT number: NCT00077428
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Adenoid Cystic Carcinoma of the Oral Cavity Recurrent Salivary Gland Cancer Salivary Gland Adenoid Cystic Carcinoma Stage III Adenoid Cystic Carcinoma of the Oral Cavity Stage III Salivary Gland Cancer Stage IV Adenoid Cystic Carcinoma of the Oral Cavity Stage IV Salivary Gland Cancer

Start date: 2004-06-01
Primary completion: 2007-06-01
Enrollment: 37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.